Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03129945
Other study ID # 2014-1085
Secondary ID UC Reliance 857
Status Completed
Phase N/A
First received
Last updated
Start date January 17, 2017
Est. completion date April 18, 2019

Study information

Verified date October 2021
Source University of California, Irvine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to determine the best medication to stop preterm labor. Recent studies have identify nifedipine and indomethacin as the two medications that are most likely to delay delivery for 48 hours, decrease maternal side effects and decrease some complications related to preterm delivery to the neonate. Both of these medications are commonly used to stop pre-term labor, therefore it has become our institution's standard to use these two medications in the setting of preterm labor. There have been limited studies comparing these two medications directly. A total of 450 participants will be asked to participate across all study sites.


Description:

There are about 10 million births that occur before 37 weeks (prior to full term gestation) that occur annually worldwide. More than 1 million infants die from complications related to preterm birth. Tocolytics, medications that stop preterm labor, have been well studied. Results regarding prolongation of pregnancy are varied, but tocolytics have been shown to delay delivery for 48 hours, allowing time to administer corticosteroids. ACOG (American Congress of Obstetrics and Gynecologists) recommends giving tocolytics to provide time for corticosteroid administration, transfer to tertiary level care and to allow for magnesium infusion to protect the neonatal brain. Corticosteroid administration when the course is completed (48 hours from first dose) decreases some of the major risks associated with prematurity. Recent meta-analyses have shown of the commonly used tocolytics, calcium channel blockers and prostaglandin inhibitors ranked consistently among the top three medications in several categories including delaying delivery by 48 hours. There have been only two published randomized control studies to date that have directly compared these two tocolytics. These studies lacked power and standardization to provide clinical guidelines. There is a high neonatal mortality and morbidity along with exceedingly high hospital costs associated with complications related to preterm birth, so it is important to intervene with superior medications. Here the investigators propose a multi institutional (based within the University of California system) randomized controlled study to directly compare nifedipine (most commonly used calcium channel blocker) to indomethacin (most commonly used prostaglandin inhibitor). Objective: The Investigator's objective is to compare the prolongation of pregnancy by 48 hours after women are diagnosed with preterm labor prior to 32 weeks gestational age and treated with either nifedipine or indomethacin. Investigators hypothesize that indomethacin will significantly arrest preterm labor by 48 hours in more women compared to nifedipine. The primary outcomes measures will be delaying preterm delivery by 48 hours; secondary outcomes measures will include delay of delivery by 7 days and decreasing delivery before 37 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date April 18, 2019
Est. primary completion date April 18, 2019
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Singleton pregnancy. A twin pregnancy reduced to singleton (either spontaneously or therapeutically) before 140 weeks by gestational age (see dating below) is acceptable. - Gestational age at randomization between 240 weeks to 315 weeks by using the dating determinations as below - Preterm labor with intact membranes. Preterm labor is defined as at least 6 regular uterine contractions in 60 minutes either seen on tocodynamometer, palpated by health providers and/or subjectively felt by the patient and at least one of the following: 1. Associated with cervical change by cervical dilation greater than or equal to 1cm OR effacement greater than or equal to 25 to 50% 2. Cervix greater than or equal to 2cm dilated on initial digital exam 3. At least 75% effaced on initial digital exam 4. Short cervical length (defined by each institution's policy) as obtained by transvaginal cervical sonography [in general, this is defined as a measurement of 2.0 - 2.5 cm or less] and/or a positive fetal fibronectin test (defined as a level greater than 50ng/mL). - Intact membranes - 18 years of age or older Exclusion Criteria: - Fetal demise, or known major fetal anomaly, including cardiac anomaly and hydrops - Maternal contraindication to nifedipine: preload cardiac lesions or maternal hypotension (systolic blood pressure less than 100 or diastolic blood pressure less than 60). A delayed dose can be given if blood pressure improves - it will be documented if dose is delayed, how long from scheduled dose it was delayed and reason for delay. - Maternal contraindication to indomethacin: platelet dysfunction or bleeding disorders, hepatic dysfunction, gastrointestinal ulcerative disease, renal dysfunction and asthma - Obstetrical contraindication to tocolysis not already mentioned: non reassuring fetal status, severe preeclampsia or eclampsia, maternal bleeding with hemodynamic instability, chorioamnionitis, preterm premature rupture of membranes - Participation in another interventional study that influences neonatal morbidity or mortality - Participation in this trial earlier in the pregnancy - Maternal allergy to either indomethacin or nifedipine - Maternal allergy to aspirin and other NSAIDs. - Maternal hypertension requiring treatment. - Maternal kidney disorder that would require adjustment in magnesium dosing.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nifedipine
Subjects will be given nifedipine 10mg orally and repeated every 20 minutes for a maximum dose of 30mg in the first hour followed by 20mg every 6 hours for the first 48 hours.
Indomethacin
Those randomized to indomethacin will be given 100mg orally as a loading dose followed by 50mg every 6 hours for the first 48 hours of treatment.

Locations

Country Name City State
United States University of California, Los Angeles Los Angeles California
United States University of California, Irvine Orange California
United States University of California, Davis Sacramento California
United States University of California, San Diego San Diego California
United States University of California, San Francisco San Francisco California

Sponsors (5)

Lead Sponsor Collaborator
University of California, Irvine University of California, Davis, University of California, Los Angeles, University of California, San Diego, University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Delay of Preterm Delivery by 48 Hours. 1. To compare the prolongation of pregnancy by 48 hours after women are diagnosed with threatened preterm labor prior to 32 weeks gestational age and treated with either nifedipine or indomethacin. The primary outcome measured will be delay of (preterm delivery) by 48 hours. Participants will be followed for the duration of the hospital stay, an expected average of 1 week
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04404686 - Vaginal Indomethacin for Preterm Labor Phase 2/Phase 3
Completed NCT03267043 - Family Nurture Intervention in the NICU at The Valley Hospital N/A
Recruiting NCT04866342 - Servo Controlled Oxygen Targeting (SCO2T) Study: Masimo vs. Nellcor N/A
Completed NCT00185952 - Nifedipine vs Placebo for Maintenance Tocolysis of Preterm Labor. N/A
Terminated NCT01840228 - Vaginal Progesterone for the Prevention of Preterm Birth in Women With Arrested Preterm Labor N/A
Completed NCT04494529 - Single Dose Antenatal Corticosteroids (SNACS) for Women at Risk of Preterm Birth Phase 3
Recruiting NCT05264779 - The Periviable GOALS Decision Support Tool N/A
Recruiting NCT05670665 - Impact of Threatened Preterm Labour in Fetal Cardiovascular and Metabolic Programming (SHs)
Recruiting NCT01317225 - Prevention of Preterm Labor in Patients With a Previous Episode of Threatened Preterm Labor With Progesterone Phase 3
Recruiting NCT05114096 - Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS) Phase 4
Completed NCT03211338 - Inflammation and Cell Maturation in Preterm Delivery Placentas - in Vitro and in Vivo Effect of Progesterone N/A
Completed NCT02710474 - Family Nurture Intervention in the NICU N/A
Terminated NCT01286246 - Randomized Controlled Trial of Vaginal Progesterone in Women With Threatened Preterm Labor Phase 4
Completed NCT04177992 - Servo Controlled Oxygen Targeting Study N/A
Recruiting NCT05685745 - Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset
Terminated NCT02021539 - The Prognostic Value of Cervical Elastography for Identifying Patients at Risk for Preterm Delivery N/A
Not yet recruiting NCT01360034 - Nifedipine Versus Indomethacin in the Treatment of Preterm Labour Phase 3
Recruiting NCT05132829 - Azithromycin to Improve Latency in Exam Indicated Cerclage Control Trial Phase 4
Completed NCT04390659 - Myomectomy During Cesarean Section Is This Aright Decision
Terminated NCT04546568 - SCO2T (Servo vs. Servo) N/A